Evidence map›Paper›PMID 34072708›Full record

ReviewAntioxidants (Basel, Switzerland)2021

The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.

Alessio Danilo Inchingolo, Gianna Dipalma, Angelo Michele Inchingolo, Giuseppina Malcangi, Luigi Santacroce, Maria Teresa D'Oria, Ciro Gargiulo Isacco, Ioana Roxana Bordea, Sebastian Candrea, Antonio Scarano and 10 more

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 8 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 8 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Review
  12. Management of Rheumatoid Arthritis in Primary Care: A Scoping Review.International journal of environmental research and public health · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Pseudoscience and fraudulent products for COVID-19 management.Environmental science and pollution research international · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 3 countries.

Alessio Danilo InchingoloDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.ORCID 0000-0002-6366-1039
Gianna DipalmaDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.ORCID 0000-0002-5947-8987
Angelo Michele InchingoloDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.
Giuseppina MalcangiDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.ORCID 0000-0001-9745-7506
Luigi SantacroceDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.ORCID 0000-0001-5671-8124
Maria Teresa D'OriaDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.ORCID 0000-0002-9376-8152
Ciro Gargiulo IsaccoDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.
Ioana Roxana BordeaDepartment of Oral Rehabilitation, University of Medicine and Pharmacy "Iuliu Hatieganu", 400012 Cluj-Napoca, Romania.ORCID 0000-0001-7166-9949
Sebastian CandreaDepartment of Oral Rehabilitation, University of Medicine and Pharmacy "Iuliu Hatieganu", 400012 Cluj-Napoca, Romania.
Antonio ScaranoDepartment of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy.ORCID 0000-0003-1374-6146
Benedetta MorandiDepartment of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, 20122 Milan, Italy.
Massimo Del FabbroDepartment of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0001-7144-0984
Marco FarronatoDepartment of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0002-6209-9873
Gianluca Martino TartagliaDepartment of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, 20122 Milan, Italy.
Mario Giosuè BalzanelliSET-118, Department of Pre-Hospital and Emergency-San Giuseppe Moscati Hospital, 74100 Taranto, Italy.
Andrea BalliniDepartment of Biosciences, Biotechnologies and Biopharmaceutics, Campus Universitario, University of Bari, 70125 Bari, Italy.ORCID 0000-0001-8758-1415
Ludovica NucciDepartment of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, 80100 Naples, Italy.
Felice LorussoDepartment of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy.ORCID 0000-0002-2660-9231
Silvio TaschieriDepartment of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, 20122 Milan, Italy.ORCID 0000-0002-7866-5024
Francesco InchingoloDepartment of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy.ORCID 0000-0003-3797-5883
University of Bari Aldo Moro · ITUniversity of Milan · ITIuliu Hațieganu University of Medicine and Pharmacy · ROUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Chieti-Pescara · ITAzienda Ospedaliera S.Giuseppe Moscati · ITSechenov University · RUUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease of 2019 (COVID-19) that emerged in December 2019 in Wuhan, China, and rapidly spread worldwide, with a daily increase in confirmed cases and infection-related deaths. The World Health Organization declared a pandemic on the 11th of March 2020. COVID-19 presents flu-like symptoms that become severe in high-risk medically compromised subjects. The aim of this study was to perform an updated overview of the treatments and adjuvant protocols for COVID-19.

methodsA systematic literature search of databases was performed (MEDLINE PubMed, Google Scholar, UpToDate, Embase, and Web of Science) using the keywords: "COVID-19", "2019-nCoV", "coronavirus" and "SARS-CoV-2" (date range: 1 January 2019 to 31st October 2020), focused on clinical features and treatments.

resultsThe main treatments retrieved were antivirals, antimalarials, convalescent plasma, immunomodulators, corticosteroids, anticoagulants, and mesenchymal stem cells. Most of the described treatments may provide benefits to COVID-19 subjects, but no one protocol has definitively proven its efficacy.

conclusionsWhile many efforts are being spent worldwide in research aimed at identifying early diagnostic methods and evidence-based effective treatments, mass vaccination is thought to be the best option against this disease in the near future.

Indexed as

anticoagulantsantimalarialsantioxidantsantiviralsautologous stem cellscorticosteroidsimmunomodulatorsimmunotherapySARS-CoV-2 (COVID-19)vaccines

Identifiers

PMID34072708
PMCPMC8226610
OpenAlexW3164022071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.